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EDITORIAL
Led by the Department of Trade and Industry 
(DTI), South Africa (SA) is undergoing a process of 
reviewing and amending national laws governing the 
protection of intellectual property (IP). This process 
has the potential to remedy significant shortcomings 
in the current legislation that allow for the granting of an excessive 
number of patents, and evergreening of monopoly periods, at the 
expense of medicine access.
As a member of the World Trade Organization, SA is required 
to uphold minimum standards of IP protection as defined by the 
international Agreement on Trade Related Aspects of Intellectual 
Property Rights (the ‘TRIPS’ agreement). The TRIPS agreement 
requires SA to grant 20 years of patent protection on products and 
processes that meet SA’s patentability criteria. These criteria are 
the standards of novelty, innovativeness and industrial applicability 
required to receive a patent.[1]
A key shortcoming of SA’s current IP system is that the majority 
of patents granted fail to meet the country’s patentability criteria.[2] 
Patents that do not meet the country’s patentability criteria are granted 
as a result of the depository system used for granting patents in the 
country without examination of their merits.[2-4]
In observing their TRIPS obligations, countries may use depository 
or examination systems for granting patents.[3-5] In countries with 
depository systems, patent applicants are simply required to file 
the correct forms and pay the requisite fees in order to receive a 
patent. In other words, nobody checks patent applications to ensure 
that patentability criteria are met prior to the granting of patents. 
Conversely, under examination systems, the merits of a patent 
application are reviewed and applicants must demonstrate that 
patentability criteria have been met in order to receive monopoly 
protection.[3,4]
Given the lack of examination in SA, many patents are granted in 
this country that are rejected by countries and regions – including 
Brazil, the USA and the European Union (EU) – that have examination 
systems in place.[4,6]
A comparative analysis showed that SA granted 66% more 
pharmaceutical patents than the USA and the EU on identical 
patent applications filed between 2000 and 2002.[6] Another study 
demonstrated that SA granted 2 442 pharmaceutical patents in 2008 
alone, while in comparison, Brazil granted only 278 in the 6 years 
between 2003 and 2008.[4]
The ease with which pharmaceutical patents are granted in SA 
permits pharmaceutical companies to gain multiple, successive 
patents on individual medicines, extending their periods of monopoly 
protection beyond the 20 years required by the TRIPS agreement. 
This practice is commonly known as ‘evergreening’.
The challenge of evergreening in SA was highlighted in recent litigation 
over patents held on the popular birth control pill containing drospirenone 
and ethinyl oestradiol, sold by pharmaceutical company Bayer as Yasmin. 
The initial 20-year period of patent protection on this medicine ended in 
2010 in SA. However, secondary, evergreening patents prevented generic 
versions from being brought to the market at a 30% price reduction when 
the initial patent expired. The Supreme Court of Appeal in Bloemfontein 
upheld Bayer’s secondary patent in 2014, which means that generic use 
may continue to be blocked until 2024. Generic versions are already 
available in the USA and countries in Europe following rejection of Bayer’s 
secondary patents in these countries.[7]
The hepatitis B medicine entecavir, marketed by Bristol-Myers 
Squibb in SA as Baraclude, further demonstrates the challenge of 
evergreening. The initial patent on this medicine expired in 2011, 
but secondary patents could prevent use of generic equivalents until 
2026. Given the high local cost of Baraclude – between ZAR4 700 
and ZAR5 500 per month for a hepatitis B patient – entecavir is not 
currently provided in the public sector. Yet generic equivalents are 
available outside SA at one-tenth of the price charged by the patent 
holder.[7]
Similarly, generic versions of aripiprazole (marketed in SA as 
Abilify), used to treat depression and bipolar disorder, are now 
available in the USA, yet secondary patents may block availability of 
generics in SA until 2033. SA consumers pay up to 35 times more for 
aripiprazole than those in India, where generic competition exists.[7]
Excessive patenting and evergreening of monopoly periods 
prevents South Africans from accessing more affordable, generic 
versions of many medicines, despite their widespread use and 
availability in other parts of the world. To address this challenge, SA 
must amend its laws and procedures for examining applications and 
granting patents.
Encouragingly, the DTI is currently undertaking a process of 
reviewing and amending SA’s IP legislation. During 2013, the DTI 
released a Draft National Policy on Intellectual Property for public 
comment that contained commitments to pro-public health reform. 
According to the DTI, the finalised policy will be adopted this year, 
after which bills to amend IP legislation will be brought before 
Parliament.
The Fix the Patent Laws coalition has called on the DTI to 
urgently release a finalised policy recommending key reforms to 
curb evergreening and improve medicine access. The Fix the Patent 
Laws coalition comprises 15 health organisations in SA that represent 
patients seeking treatment and care in the realms of HIV, tuberculosis, 
sexual and reproductive health, cancer, mental health conditions, 
diabetes and other non-communicable diseases.
The reforms recommended by the Fix the Patent Laws coalition 
include, among others, setting stricter patent standards and requiring 
examination of pharmaceutical patent applications.
Under the TRIPS agreement, SA has the flexibility to set stricter 
patentability criteria that explicitly restrict patent evergreening. 
TRIPS-compliant countries – India, Argentina and the Philippines – 
have adopted legislation or patent examination guidelines that limit 
or prevent patenting of new formulations (new dosages, combinations 
or forms (i.e. isomers, salts or polymorphs) of existing medicines) 
and new uses (new clinical uses of medicines other than those for 
which they are already registered or sold), except in very limited 
circumstances. Brazil is currently considering legislation to restrict 
these types of patents. In amending its patent legislation, SA should 
adopt similarly strict criteria to ensure that only truly innovative 
compounds and processes are granted monopoly protection.
In addition to setting stricter patentability criteria, SA must amend 
its system for granting patents to ensure that only patents meeting 
patentability criteria are granted. To do this, the country must 
replace its depository system with an examination system. In order 
to implement patent examination, SA will have to overcome capacity 
challenges.
The feasibility of an examination system in SA is currently the 
subject of rigorous debate.[8] Discussions have centred largely on 
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the human resource requirements for implementing examination, 
and whether SA can attract and hire sufficient numbers of qualified 
examiners. Patent examiners often have advanced degrees in their 
fields, and must have sufficient technical knowledge to judge the 
merits of a patent application. During 2013, the Indian Patents Office 
reported that 337 patent examiners were employed in the country.[5]
Attracting and hiring sufficient patent examiners will be a hurdle 
to implementing examination in SA. However, there are different 
approaches and models that could be pursued.[1,3]
A partial or phased approach
A partial or phased approach would initially focus on implementing 
examination for a few key sectors. This would reduce the number 
of examiners that the country would initially need to hire and train, 
allowing for capacity building over time. A partial or phased-in 
approach should initially focus on implementing examination for 
sectors that impact on government’s ability to achieve its constitutional 
obligations – such as realising the right to health.[1,3]
A collaborative approach
A collaborative approach would allow SA to share the workload of 
examination with the patent offices of other countries or regions. 
If SA were to draw on decisions from other patent offices, many 
applications could be rejected automatically. However, in pursuing 
such an approach, careful consideration would have to be paid as to 
which patent offices ought to be selected for collaboration, taking 
into account that country and regional IP priorities and patentability 
criteria frequently differ. A rational approach would be for SA to 
collaborate with patents offices with comparable patentability criteria 
and adequate capacity for examination, in countries with similar 
socioeconomic backgrounds.[3]
An opposition approach
Patent opposition procedures are commonly used in many TRIPS-
compliant developed, and developing, country patent offices with 
examination systems in place.
An opposition approach would allow the SA Patents Office to draw 
on expertise from third parties operating in industry and civil society 
in determining whether patents should be granted. An opposition 
approach would require patent law reform to allow third parties (such 
as competing companies or NGOs) to comment on the validity of 
patents prior to and/or shortly after they are granted. This approach 
should be adopted together with a phased and/or collaborative 
approach.
For an opposition approach to work, information regarding 
pending, or recently granted, patents must be made publicly available. 
Additionally, third parties must be allowed to submit evidence to 
the SA Patents Office when patentability criteria have not been met 
during a designated time frame.[1,3]
Conclusion
While capacity challenges are a concern in implementing patent 
examination, given the negative impact of abusive patenting 
on medicines access, they should be assessed and dealt with 
accordingly. Implementing an opposition approach together with a 
partial/phased-in approach and/or a collaborative approach – or a 
combination of all these approaches – can assist SA in overcoming 
capacity constraints.
Currently, the only way for third parties to oppose the granting of 
patents in SA is through undertaking lengthy and expensive judicial 
challenges – despite the fact that patents are granted without ever 
assessing whether or not patentability criteria have been met.[1] 
Frankly, SA’s market is too small for most generic companies to bear 
the risk and cost of such a judicial challenge.
Adopting stricter patentability criteria, and implementing patent 
examination in SA, would significantly reduce the number of patents 
granted. Granting fewer patents will, in turn, facilitate generic 
competition, lower medicine prices, and ensure increased access 
to medicines for individuals who are currently unable to afford the 
treatments that they need, and for the government in its procurement 
of medicines for the public sector.
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